DrugPatentWatch Database Preview
NPLATE Drug Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
Summary for Tradename: NPLATE
| Patents: | 21 |
| Applicants: | 1 |
| BLAs: | 1 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for NPLATE |
Recent Clinical Trials for NPLATE
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| Amgen | Phase 3 |
| University Children's Hospital Basel | Phase 4 |
| University Hospital, Basel, Switzerland | Phase 4 |
Pharmacology for NPLATE
| Mechanism of Action | Thrombopoietin Receptor Agonists |
| Physiological Effect | Increased Megakaryocyte Maturation Increased Platelet Production |
Company Disclosures: US Patents for NPLATE
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2018-10-23 | RX | Orphan | company |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2018-10-23 | RX | Orphan | company |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | Amgen Inc. (Thousand Oaks, CA) | 2018-10-23 | RX | Orphan | company |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Patent Text Search: US Patents for NPLATE
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) | 2033-03-11 | RX | Orphan | search |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | University of the Sciences of Philadelphia (Philadelphia, PA) | 2034-11-21 | RX | Orphan | search |
| Amgen | NPLATE | romiplostim | INJECTABLE; SUBCUTANEOUS | 125268 | 001 | 2008-08-22 | Start Trial | AMGEN INC. (Thousand Oaks, CA) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for NPLATE
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2840431 | Start Trial |
| Eurasian Patent Organization | 200100464 | Start Trial |
| Japan | 2007084555 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for NPLATE
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 25/2009 | Austria | Start Trial | PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| 122009000039 | Germany | Start Trial | PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204 |
| SPC/GB09/035 | United Kingdom | Start Trial | SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB09/035 GRANTED TO KIRIN-AMGEN INC. IN RESPECT OF THE PRODUCT ROMIPLOSTIM, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6361 DATED 20/04/2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 05/02/2024. |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
